Skip to search formSkip to main contentSkip to account menu

glatiramer acetate

Known as: COP-1, L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt), Copolymer-1 
A random polymer of L-ALANINE, L-GLUTAMIC ACID, L-LYSINE, and L-TYROSINE that structurally resembles MYELIN BASIC PROTEIN. It is used in the… 
National Institutes of Health

Related topics

Related topics

21 relations
1 ML glatiramer acetate 40 MG/ML Prefilled Syringe [Copaxone]Drug AllergyIn BloodMultiple Sclerosis, Relapsing-Remitting

Broader (4)

Antirheumatic AgentsGlatiramerImmunologic AdjuvantsImmunosuppressive Agents

Narrower (3)

CopaxoneGlatopaTV 5010

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
Background Approximately one-third of patients with multiple sclerosis (MS) are unresponsive to, or intolerant of, interferon… 
Review
2010
Review
2010
Glatiramer acetate for multiple sclerosis.
BACKGROUND This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2004… 
Highly Cited
2007
Highly Cited
2007
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers
Genetic-based optimization of treatment prescription is becoming a central research focus in the management of chronic diseases… 
Highly Cited
2006
Highly Cited
2006
Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
Mitoxantrone has been approved by the FDA for worsening relapsing remitting and secondary progressive Multiple Sclerosis. However… 
Highly Cited
2002
Highly Cited
2002
Thermoplastic elastomer hydrogels via self-assembly of an elastin-mimetic triblock polypeptide
Synthetic polymers consisting of well-defined blocks of compositionally dissimilar monomers undergo microscopic phase separation… 
Highly Cited
2001
Highly Cited
2001
HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis
Background: Copolymer 1 (Cop-1) is a random synthetic amino acid copolymer, effective in the treatment of the relapsing-remitting… 
Review
1999
Review
1999
The Decade of Autoimmunity
Highly Cited
1997
Highly Cited
1997
New treatments and azathioprine in multiple sclerosis
Highly Cited
1996
Highly Cited
1996
The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: Effect of copolymer 1 on MOG-induced disease
Multiple sclerosis (MS), an autoimmune disease of the central nervous system (CNS) characterized by primary demyelination, is… 
Highly Cited
1983
Highly Cited
1983
Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)